
Global Long-acting PrEP Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Long-acting PrEP market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Long-acting PrEP is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Long-acting PrEP is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Long-acting PrEP market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Long-acting PrEP is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Long-acting PrEP market include ViiV Healthcare and Gilead Sciences etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Long-acting PrEP, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Long-acting PrEP, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting PrEP, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-acting PrEP sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-acting PrEP market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-acting PrEP sales, projected growth trends, production technology, application and end-user industry.
Long-acting PrEP Segment by Company
ViiV Healthcare
Gilead Sciences
Long-acting PrEP Segment by Type
Cabotegravir
Lenacapavir
Other
Long-acting PrEP Segment by Application
Hospital
Clinic
Other
Long-acting PrEP Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Long-acting PrEP status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Long-acting PrEP market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Long-acting PrEP significant trends, drivers, influence factors in global and regions.
6. To analyze Long-acting PrEP competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting PrEP market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting PrEP and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting PrEP.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Long-acting PrEP market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting PrEP industry.
Chapter 3: Detailed analysis of Long-acting PrEP manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Long-acting PrEP in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Long-acting PrEP in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Long-acting PrEP market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Long-acting PrEP is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Long-acting PrEP is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Long-acting PrEP market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Long-acting PrEP is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Long-acting PrEP market include ViiV Healthcare and Gilead Sciences etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Long-acting PrEP, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Long-acting PrEP, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting PrEP, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-acting PrEP sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-acting PrEP market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-acting PrEP sales, projected growth trends, production technology, application and end-user industry.
Long-acting PrEP Segment by Company
ViiV Healthcare
Gilead Sciences
Long-acting PrEP Segment by Type
Cabotegravir
Lenacapavir
Other
Long-acting PrEP Segment by Application
Hospital
Clinic
Other
Long-acting PrEP Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Long-acting PrEP status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Long-acting PrEP market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Long-acting PrEP significant trends, drivers, influence factors in global and regions.
6. To analyze Long-acting PrEP competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting PrEP market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting PrEP and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting PrEP.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Long-acting PrEP market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting PrEP industry.
Chapter 3: Detailed analysis of Long-acting PrEP manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Long-acting PrEP in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Long-acting PrEP in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
194 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Long-acting PrEP Sales Value (2020-2031)
- 1.2.2 Global Long-acting PrEP Sales Volume (2020-2031)
- 1.2.3 Global Long-acting PrEP Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Long-acting PrEP Market Dynamics
- 2.1 Long-acting PrEP Industry Trends
- 2.2 Long-acting PrEP Industry Drivers
- 2.3 Long-acting PrEP Industry Opportunities and Challenges
- 2.4 Long-acting PrEP Industry Restraints
- 3 Long-acting PrEP Market by Company
- 3.1 Global Long-acting PrEP Company Revenue Ranking in 2024
- 3.2 Global Long-acting PrEP Revenue by Company (2020-2025)
- 3.3 Global Long-acting PrEP Sales Volume by Company (2020-2025)
- 3.4 Global Long-acting PrEP Average Price by Company (2020-2025)
- 3.5 Global Long-acting PrEP Company Ranking (2023-2025)
- 3.6 Global Long-acting PrEP Company Manufacturing Base and Headquarters
- 3.7 Global Long-acting PrEP Company Product Type and Application
- 3.8 Global Long-acting PrEP Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Long-acting PrEP Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Long-acting PrEP Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Long-acting PrEP Market by Type
- 4.1 Long-acting PrEP Type Introduction
- 4.1.1 Cabotegravir
- 4.1.2 Lenacapavir
- 4.1.3 Other
- 4.2 Global Long-acting PrEP Sales Volume by Type
- 4.2.1 Global Long-acting PrEP Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Long-acting PrEP Sales Volume by Type (2020-2031)
- 4.2.3 Global Long-acting PrEP Sales Volume Share by Type (2020-2031)
- 4.3 Global Long-acting PrEP Sales Value by Type
- 4.3.1 Global Long-acting PrEP Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Long-acting PrEP Sales Value by Type (2020-2031)
- 4.3.3 Global Long-acting PrEP Sales Value Share by Type (2020-2031)
- 5 Long-acting PrEP Market by Application
- 5.1 Long-acting PrEP Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Long-acting PrEP Sales Volume by Application
- 5.2.1 Global Long-acting PrEP Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Long-acting PrEP Sales Volume by Application (2020-2031)
- 5.2.3 Global Long-acting PrEP Sales Volume Share by Application (2020-2031)
- 5.3 Global Long-acting PrEP Sales Value by Application
- 5.3.1 Global Long-acting PrEP Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Long-acting PrEP Sales Value by Application (2020-2031)
- 5.3.3 Global Long-acting PrEP Sales Value Share by Application (2020-2031)
- 6 Long-acting PrEP Regional Sales and Value Analysis
- 6.1 Global Long-acting PrEP Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Long-acting PrEP Sales by Region (2020-2031)
- 6.2.1 Global Long-acting PrEP Sales by Region: 2020-2025
- 6.2.2 Global Long-acting PrEP Sales by Region (2026-2031)
- 6.3 Global Long-acting PrEP Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Long-acting PrEP Sales Value by Region (2020-2031)
- 6.4.1 Global Long-acting PrEP Sales Value by Region: 2020-2025
- 6.4.2 Global Long-acting PrEP Sales Value by Region (2026-2031)
- 6.5 Global Long-acting PrEP Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Long-acting PrEP Sales Value (2020-2031)
- 6.6.2 North America Long-acting PrEP Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Long-acting PrEP Sales Value (2020-2031)
- 6.7.2 Europe Long-acting PrEP Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Long-acting PrEP Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Long-acting PrEP Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Long-acting PrEP Sales Value (2020-2031)
- 6.9.2 South America Long-acting PrEP Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Long-acting PrEP Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Long-acting PrEP Sales Value Share by Country, 2024 VS 2031
- 7 Long-acting PrEP Country-level Sales and Value Analysis
- 7.1 Global Long-acting PrEP Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Long-acting PrEP Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Long-acting PrEP Sales by Country (2020-2031)
- 7.3.1 Global Long-acting PrEP Sales by Country (2020-2025)
- 7.3.2 Global Long-acting PrEP Sales by Country (2026-2031)
- 7.4 Global Long-acting PrEP Sales Value by Country (2020-2031)
- 7.4.1 Global Long-acting PrEP Sales Value by Country (2020-2025)
- 7.4.2 Global Long-acting PrEP Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.9.2 France Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.16.2 China Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.19.2 India Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Long-acting PrEP Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Long-acting PrEP Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Long-acting PrEP Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 ViiV Healthcare
- 8.1.1 ViiV Healthcare Comapny Information
- 8.1.2 ViiV Healthcare Business Overview
- 8.1.3 ViiV Healthcare Long-acting PrEP Sales, Value and Gross Margin (2020-2025)
- 8.1.4 ViiV Healthcare Long-acting PrEP Product Portfolio
- 8.1.5 ViiV Healthcare Recent Developments
- 8.2 Gilead Sciences
- 8.2.1 Gilead Sciences Comapny Information
- 8.2.2 Gilead Sciences Business Overview
- 8.2.3 Gilead Sciences Long-acting PrEP Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Gilead Sciences Long-acting PrEP Product Portfolio
- 8.2.5 Gilead Sciences Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Long-acting PrEP Value Chain Analysis
- 9.1.1 Long-acting PrEP Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Long-acting PrEP Sales Mode & Process
- 9.2 Long-acting PrEP Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Long-acting PrEP Distributors
- 9.2.3 Long-acting PrEP Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.